S&P 500   4,565.64 (+0.24%)
DOW   35,537.61 (+0.34%)
QQQ   391.18 (+0.25%)
AAPL   189.41 (-0.52%)
MSFT   379.10 (-0.94%)
META   333.72 (-1.55%)
GOOGL   135.36 (-1.34%)
AMZN   146.71 (-0.22%)
TSLA   247.13 (+0.17%)
NVDA   481.87 (+0.77%)
NIO   7.22 (+0.14%)
BABA   74.88 (-2.42%)
AMD   124.66 (+2.17%)
T   16.25 (+0.43%)
F   10.66 (+2.80%)
MU   76.99 (+1.14%)
CGC   0.56 (+3.89%)
GE   119.33 (+0.40%)
DIS   92.97 (+0.51%)
AMC   7.23 (+7.91%)
PFE   30.12 (+1.45%)
PYPL   58.62 (+0.26%)
XOM   103.50 (-0.38%)
S&P 500   4,565.64 (+0.24%)
DOW   35,537.61 (+0.34%)
QQQ   391.18 (+0.25%)
AAPL   189.41 (-0.52%)
MSFT   379.10 (-0.94%)
META   333.72 (-1.55%)
GOOGL   135.36 (-1.34%)
AMZN   146.71 (-0.22%)
TSLA   247.13 (+0.17%)
NVDA   481.87 (+0.77%)
NIO   7.22 (+0.14%)
BABA   74.88 (-2.42%)
AMD   124.66 (+2.17%)
T   16.25 (+0.43%)
F   10.66 (+2.80%)
MU   76.99 (+1.14%)
CGC   0.56 (+3.89%)
GE   119.33 (+0.40%)
DIS   92.97 (+0.51%)
AMC   7.23 (+7.91%)
PFE   30.12 (+1.45%)
PYPL   58.62 (+0.26%)
XOM   103.50 (-0.38%)
S&P 500   4,565.64 (+0.24%)
DOW   35,537.61 (+0.34%)
QQQ   391.18 (+0.25%)
AAPL   189.41 (-0.52%)
MSFT   379.10 (-0.94%)
META   333.72 (-1.55%)
GOOGL   135.36 (-1.34%)
AMZN   146.71 (-0.22%)
TSLA   247.13 (+0.17%)
NVDA   481.87 (+0.77%)
NIO   7.22 (+0.14%)
BABA   74.88 (-2.42%)
AMD   124.66 (+2.17%)
T   16.25 (+0.43%)
F   10.66 (+2.80%)
MU   76.99 (+1.14%)
CGC   0.56 (+3.89%)
GE   119.33 (+0.40%)
DIS   92.97 (+0.51%)
AMC   7.23 (+7.91%)
PFE   30.12 (+1.45%)
PYPL   58.62 (+0.26%)
XOM   103.50 (-0.38%)
S&P 500   4,565.64 (+0.24%)
DOW   35,537.61 (+0.34%)
QQQ   391.18 (+0.25%)
AAPL   189.41 (-0.52%)
MSFT   379.10 (-0.94%)
META   333.72 (-1.55%)
GOOGL   135.36 (-1.34%)
AMZN   146.71 (-0.22%)
TSLA   247.13 (+0.17%)
NVDA   481.87 (+0.77%)
NIO   7.22 (+0.14%)
BABA   74.88 (-2.42%)
AMD   124.66 (+2.17%)
T   16.25 (+0.43%)
F   10.66 (+2.80%)
MU   76.99 (+1.14%)
CGC   0.56 (+3.89%)
GE   119.33 (+0.40%)
DIS   92.97 (+0.51%)
AMC   7.23 (+7.91%)
PFE   30.12 (+1.45%)
PYPL   58.62 (+0.26%)
XOM   103.50 (-0.38%)

Eiger BioPharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR)

$0.33
+0.00 (+0.06%)
(As of 01:18 PM ET)
Compare
Today's Range
$0.32
$0.34
50-Day Range
$0.22
$0.43
52-Week Range
$0.21
$4.62
Volume
42,258 shs
Average Volume
457,652 shs
Market Capitalization
$14.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Eiger BioPharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,615.1% Upside
$5.67 Price Target
Short Interest
Healthy
2.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.96mentions of Eiger BioPharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$44,181 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.64) to ($0.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

41st out of 949 stocks

Biological Products, Except Diagnostic Industry

5th out of 162 stocks


EIGR stock logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR Stock Price History

EIGR Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Eiger to discontinue hepatitis drug study
Citi Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,615.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-96,780,000.00
Net Margins
-590.80%
Pretax Margin
-590.79%

Debt

Sales & Book Value

Annual Sales
$13.48 million
Book Value
($0.04) per share

Miscellaneous

Free Float
42,814,000
Market Cap
$14.66 million
Optionable
Not Optionable
Beta
1.89
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. David Apelian M.B.A. (Age 58)
    M.D., Ph.D., CEO & Director
    Comp: $204.39k
  • Dr. Jeffrey S. Glenn M.D. (Age 60)
    Ph.D., Scientific Founder & Independent Director
    Comp: $67k
  • Mr. Eldon C. Mayer IIIMr. Eldon C. Mayer III (Age 62)
    M.B.A., Chief Commercial Officer
    Comp: $586.96k
  • Mr. William G. Kaichoff CPA (Age 57)
    CFO and Principal Financial & Accounting Officer
  • Mr. Christopher A. Kurtz (Age 56)
    Chief Technical Officer
  • Mr. James Vollins J.D. (Age 54)
    General Counsel, Chief Compliance Officer & Corporate Secretary
  • Dr. Ingrid C. Choong
    Senior Vice President of Clinical Development
  • Dr. Colin Hislop M.D. (Age 65)
    MBBS, Senior Vice President of Clinical & Development Operations














EIGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $3.00 to $9.00. On average, they anticipate the company's share price to reach $5.67 in the next twelve months. This suggests a possible upside of 1,615.1% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2023?

Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of the year. Since then, EIGR stock has decreased by 72.0% and is now trading at $0.3304.
View the best growth stocks for 2023 here
.

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,010,000 shares, a decrease of 5.6% from the October 31st total of 1,070,000 shares. Based on an average trading volume of 324,600 shares, the days-to-cover ratio is presently 3.1 days.
View Eiger BioPharmaceuticals' Short Interest
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.07. The biotechnology company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period last year, the firm posted ($0.52) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock ?

Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (5.98%), GSA Capital Partners LLP (0.80%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Richard A Kayne, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EIGR) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -